維亞生物(01873.HK)擬收購朗華製藥60%股權
格隆匯5月20日丨維亞生物(01873.HK)宣佈,於2020年5月20日,潛在賣方(即朗華製藥的現有股東)接納公司間接全資附屬公司維亞生物科技(上海)遞交的函件,據此,維亞生物科技(上海)同意就自潛在賣方潛在收購朗華製藥的60%股權向潛在賣方支付按金人民幣200萬元,並按照關鍵條款進行有關潛在收購的磋商。
董事會認為,倘潛在收購落實,將令集團憑藉新增高質素人才及設施,進一步加強及多元化其藥品研發及製造能力。董事會預期,朗華製藥的業務將與集團的現有業務實現協同,並對集團的聲譽及整體業務及營運的服務供應具有重大戰略意義。朗華製藥的能力可令集團向客户提供更優質的服務,並增強集團的市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.